文献速递真菌感染

经肠内喂养管给予碾碎泊沙康唑片与打开艾沙康唑鎓硫酸胶囊并治疗药物监测

Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

该回顾性病例系列纳入2019年10月至2021年6月间经肠内喂养管给予泊沙康唑或艾沙康唑并同时进行治疗药物监测的患者,共37例38个疗程。首次评估时多数患者血药浓度达标(泊沙康唑71.5%,艾沙康唑83.3%),达标者平均浓度分别为1.61±0.77 mg/L和2.07±1.1 mg/L;初始未达标者除1例外经剂量调整后均达标。

要点

  • 经肠内喂养管给予碾碎泊沙康唑缓释片或打开艾沙康唑胶囊并结合治疗药物监测,多数患者可达目标血药浓度。
  • 首次评估达标率:泊沙康唑71.5%,艾沙康唑83.3%。
  • 初始未达标者除1例外,经剂量调整后均达目标浓度。

核心结论

  • 该病例系列表明,经肠内喂养管给予艾沙康唑和泊沙康唑并同时进行治疗药物监测,可使多数患者达到目标血浆浓度。

研究设计与样本

  • 回顾性病例系列,通过审查药房记录识别2019年10月至2021年6月间经肠内喂养管给予泊沙康唑或艾沙康唑并同时进行治疗药物监测的患者。
  • 共识别37例患者、38个肠内喂养管给予艾沙康唑或泊沙康唑的疗程。

主要发现

  • 多数患者为肺移植后初级预防(64.9%)。
  • 首次评估时血浆浓度达标者:泊沙康唑71.5%,艾沙康唑83.3%。
  • 平均血药浓度:泊沙康唑1.61±0.77 mg/L,艾沙康唑2.07±1.1 mg/L。
  • 初始评估未达标的患者中,除1例外,其余经剂量调整后均达到目标浓度。
  • 所有艾沙康唑患者及多数泊沙康唑患者使用标准维持剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isavuconazole and posaconazole are commonly used for both prophylaxis and treatment of invasive fungal infections. These agents are formulated for oral administration as a capsule and delayed release (DR) tablet or suspension, respectively. In patients unable to swallow, alternative means of administration, such as crushing posaconazole DR tablets and opening isavuconazole capsules, may be used to avoid IV administration or use of posaconazole suspension, which often produces subtherapeutic concentrations. OBJECTIVES: To assess the feasibility of achieving target plasma drug concentrations with enteral feeding tube (EFT) administration of crushed posaconazole DR tablets and opened isavuconazole capsules. METHODS: We retrospectively reviewed pharmacy records to identify patients receiving EFT administration of posaconazole or isavuconazole with concurrent therapeutic drug monitoring from October 2019 to June 2021. Plasma concentrations of either agent as well as clinical outcomes were documented. RESULTS: We identified 37 patients receiving 38 courses of EFT isavuconazole or posaconazole. The majority of patients received primary prophylaxis following lung transplantation (64.9%). Plasma concentrations upon first assessment were therapeutic in the majority of patients (posaconazole 71.5%, isavuconazole 83.3%) with a mean level of 1.61 ± 0.77 mg/L for posaconazole and 2.07 ± 1.1 mg/L for isavuconazole. Of those that were subtherapeutic on initial assessment, all but one subsequently achieved target levels upon dose titration. Standard maintenance doses were used in all isavuconazole and most posaconazole patients. CONCLUSIONS: Our case series demonstrates that isavuconazole and posaconazole can be administered via EFT with concurrent therapeutic drug monitoring to achieve target plasma concentrations in the majority of patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Dieringer TD, Schaenman JM, Davis MR, et al. Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules. J Antimicrob Chemother. 2022. PMID: 35174391. doi:10.1093/jac/dkac035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。